Efficacy and Safety of Adding Concomitant Chemotherapy to First-Line EGFR-TKI Therapy in Advanced EGFR-Mutated NSCLC: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis
The benefit of adding chemotherapy to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced EGFR-mutated non-small-cell lung cancer (NSCLC) remains uncertain. We evaluated the efficacy and safety of EGFR-TKI plus chemotherapy versus EGFR-TKI monotherapy. PubMed, Embase, and the Cochrane Library were searched from inception to August 2026 for randomized controlled trials (RCTs) comparing first-line EGFR-TKI plus chemotherapy with EGFR-TKI monotherapy in adults with advanced EGFR-mutated NSCLC. Random-effects models were used to pool hazard ratios (HRs) and risk ratios (RRs) with 95% CIs. Subgroup, sensitivity, trial sequential analysis, and GRADE assessments were performed. Seven RCTs involving 2454 patients were included. Combination therapy significantly improved overall survival (HR: 0.64; 95% CI: 0.53-0.77) and progression-free survival (HR: 0.54; 95% CI: 0.45-0.64) compared with EGFR-TKI monotherapy. Objective response rate was also higher with combination therapy (RR: 1.14; 95% CI: 1.07-1.20). However, combination therapy substantially increased treatment-related toxicity, particularly grade ≥3 and hematologic adverse events. Sensitivity analyses supported the robustness of the primary efficacy findings. Subgroup analyses demonstrated consistent OS and PFS benefits across EGFR-TKI generations. Adding chemotherapy to first-line EGFR-TKI therapy improves survival and tumor response in advanced EGFR-mutated NSCLC but increases treatment-related toxicity. These findings support combination therapy while highlighting the need to balance clinical benefit against treatment burden.
Authors
- Asad Ullah Nawaz (ORCID: https://orcid.org/0009-0007-8996-2474)
- Hassaan Abid (ORCID: https://orcid.org/0009-0008-8968-861X)
- Muhammad Maaz Amjad (ORCID: https://orcid.org/0009-0007-9252-1979)
- Sohana Memon (ORCID: https://orcid.org/0009-0003-0998-6371)
- Mariya Khan
- Mansoor Khalid (ORCID: https://orcid.org/0009-0007-7099-0125)
- Muhammad H. Khattak
- Yusra Iqbal
- Muhammad F.I. Khan
Institutions
- Liaquat University of Medical & Health Sciences (PK)
- Khyber Medical College (PK)
- Khyber Girls Medical College (PK)
- United Medical and Dental College (PK)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1097/coc.0000000000001393
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00